Protalix BioTherapeutics
PLX
31 hedge funds and large institutions have $5.05M invested in Protalix BioTherapeutics in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 9 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
31% more capital invested
Capital invested by funds: $3.86M → $5.05M (+$1.2M)
0.13% more ownership
Funds ownership: 0.6% → 0.73% (+0.13%)
6% less funds holding
Funds holding: 33 → 31 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
68% less call options, than puts
Call options by funds: $46K | Put options by funds: $142K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$423K |
| 2 |
JGC
J. Goldman & Co
New York
|
+$211K |
| 3 |
Renaissance Technologies
New York
|
+$130K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$76.5K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.9K |
| 2 |
VanEck Associates
New York
|
-$34K |
| 3 |
VF
Virtu Financial
New York
|
-$24.8K |
| 4 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$12.8K |
| 5 |
BRWM
B. Riley Wealth Management
Memphis,
Tennessee
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$43.9K | -10,382 | Closed |
|
|
28
VanEck Associates
New York
| – | -$34K | -7,732 | Closed |
|
|
PVH
29
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$12.8K | -3,036 | -97% |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$8K | -2,030 | Closed |
|
|
BRWM
31
B. Riley Wealth Management
Memphis,
Tennessee
| – | -$8K | -1,833 | Closed |
|
|
AA
32
Advisory Alpha
Holland,
Michigan
| – | -$2K | -500 | Closed |
|
|
KPW
33
Kore Private Wealth
New York
| – | -$2K | -500 | Closed |
|
34
Morgan Stanley
New York
| – | +$42 | +10 | +26% |
|
|
SPIA
35
Steward Partners Investment Advisory
New York
| – | +$845 | +200 | New |
|
PLX Hedge Fund Activity: Q2 2019 in Review
31 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2019, worth a combined $5.05M — up 31% from $3.86M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLX and 7 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $423K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $43.9K sold.
- 31 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2019, down from 33 in Q1 2019.
- Funds reported $5.05M of Protalix BioTherapeutics stock for Q2 2019, up 31% quarter-over-quarter.
- 7 funds opened new Protalix BioTherapeutics positions in Q2 2019 and 9 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2019 was Opaleye Management, an estimated $423K added.
- The largest Protalix BioTherapeutics seller in Q2 2019 was Susquehanna International Group, an estimated $43.9K sold.
Based on aggregated 13F filings for Q2 2019.